[10]
Mardis, E.R.; Ding, L.; Dooling, D.J.; Larson, D.E.; McLellan, M.D.; Chen, K.; Koboldt, D.C.; Fulton, R.S.; Delehaunty, K.D.; McGrath, S.D.; Fulton, L.A.; Locke, D.P.; Magrini, V.J.; Abbott, R.M.; Vickery, T.L.; Reed, J.S.; Robinson, J.S.; Wylie, T.; Smith, S.M.; Carmichael, L.; Eldred, J.M.; Harris, C.C.; Walker, J.; Peck, J.B.; Du, F.; Dukes, A.F.; Sanderson, G.E.; Brummett, A.M.; Clark, E.; McMichael, J.F.; Meyer, R.J.; Schindler, J.K.; Pohl, C.S.; Wallis, J.W.; Shi, X.; Lin, L.; Schmidt, H.; Tang, Y.; Haipek, C.; Wiechert, M.E.; Ivy, J.V.; Kalicki, J.; Elliott, G.; Ries, R.E.; Payton, J.E.; Westervelt, P.; Tomasson, M.H.; Watson, M.A.; Baty, J.; Heath, S.; Shannon, W.D.; Nagarajan, R.; Link, D.C.; Walter, M.J.; Graubert, T.A.; DiPersio, J.F.; Wilson, R.K.; Ley, T.J. Recurring mutations found by sequencing an acute myeloid leukemia genome.
N. Engl. J. Med., 2009,
361(11), 1058-1066.
[
http://dx.doi.org/10.1056/NEJMoa0903840] [PMID:
19657110]
[57]
Tallman, M.S.; Knight, R.D.; Glasmacher, A.G.; Dohner, H. IDHENTIFY Study Investigators Group. Phase III randomized, open-label study comparing the efficacy and safety of AG-221 vs conventional care regimens (CCR) in older patients with advanced acute myeloid leukemia (AML) with isocitrate dehydrogenase (IDH)-2 mutations in relapse or refractory to multiple prior treatments: The IDH ENTIFY trial. J. Clin. Oncol., 2016, 34(15suppl), TPS7074-TPS7074.
[58]
Pollyea, D.A.; Tallman, M.S.; de Botton, S.; Kantarjian, H.M.; Collins, R.; Stein, A.S.; Frattini, M.G.; Xu, Q.; Tosolini, A.; See, W.L.; MacBeth, K.J. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia, 2019, 33(11), 2575-2584.
[61]
Watts, J.M.; Baer, M.R.; Lee, S.; Yang, J.; Dinner, S.N.; Prebet, T.; Schiller, G.J.; Seiter, K.; Ferrell, P.B.; Kelly, P.F. A Phase 1 dose escalation study of the IDH1 M inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). J. Clin. Oncol., 2018, 36(15Suppl), 7009-7009.
[70]
Chaturvedi, A.; Gupta, C.; Goparaju, R.; Gabdoulline, R.; Kaulfuss, S.; Görlich, K.; Schottmann, R.; Panknin, O.; Wagner, M.; Geffers, R. Synergistic activity of IDH1 Inhibitor bay-1436032 with azacitidine in IDH1 mutant acute myeloid leukemia. Blood, 2017, 130(Suppl. 1), 1352.
[71]
DiNardo, C.D.; Stein, A.S.; Fathi, A.T.; Montesinos, P.; Odenike, O.; Kantarjian, H.M.; Stone, R.M.; Koralek, D.O.; Van Oostendorp, J.; Gong, J. Mutant Isocitrate dehydrogenase (mIDH) Inhibitors, enasidenib or ivosidenib, in combination with azacitidine (AZA): Preliminary results of a phase 1b/2 study in patients with newly diagnosed acute myeloid leukemia (AML). Blood, 2017, 130(Suppl. 1), 639.
[72]
DiNardo, C.D.; Stein, A.S.; Stein, E.M.; Fathi, A.T.; Schuh, A.C.; Montesinos Fernández, P.; Odenike, O.; Kantarjian, H.M.; Stone, R.M.; Collins, R. Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML). J. Clin. Oncol., 2018, 36(15)(Suppl.), 7042-7042.
[73]
DiNardo, C.D.; Stein, A.S.; Stein, E.M.; Fathi, A.T.; Frankfurt, O.; Schuh, A.C.; Martinelli, G.; Patel, P.A.; Raffoux, E.; Tan, P. Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML). J. Clin. Oncol., 2019, 37(15)(Suppl.), 7011-7011.
[74]
Stein, E.; Dinardo, C.D.; Jang, J.H.; Miyazaki, Y.; Ovilla Martinez, R.; Auer, J.; Zhang, V.; Koralek, D.O.; Wu, B. AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation. J. Clin. Oncol., 2018, 36(15)(Suppl.), TPS7074-TPS7074.
[82]
Stein, E.M.; DiNardo, C.D.; Mims, A.S.; Savona, M.R.; Pratz, K.; Stein, A.S.; Fathi, A.T.; Stone, R.M.; Pollyea, D.A.; Odenike, O. Ivosidenib or enasidenib combined with standard induction chemotherapy is well tolerated and active in patients with newly diagnosed AML with an IDH1 or IDH2 mutation: Initial results from a phase 1 trial. Blood, 2017, 130(Suppl. 1), 726.